CASI Pharmaceuticals, Inc. (CASI): Price and Financial Metrics
GET POWR RATINGS... FREE!
CASI POWR Grades
- CASI scores best on the Sentiment dimension, with a Sentiment rank ahead of 98.41% of US stocks.
- The strongest trend for CASI is in Sentiment, which has been heading up over the past 86 days.
- CASI's current lowest rank is in the Momentum metric (where it is better than 3.73% of US stocks).
CASI Stock Summary
- CASI PHARMACEUTICALS INC's market capitalization of $27,076,199 is ahead of merely 8.6% of US-listed equities.
- With a year-over-year growth in debt of 176.75%, CASI PHARMACEUTICALS INC's debt growth rate surpasses 92.12% of about US stocks.
- The volatility of CASI PHARMACEUTICALS INC's share price is greater than that of 92.56% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to CASI PHARMACEUTICALS INC are CDNA, SMRT, VMEO, WRAP, and AMST.
- CASI's SEC filings can be seen here. And to visit CASI PHARMACEUTICALS INC's official web site, go to www.casipharmaceuticals.com.
CASI Valuation Summary
- In comparison to the median Healthcare stock, CASI's price/sales ratio is 65.85% lower, now standing at 0.7.
- Over the past 243 months, CASI's EV/EBIT ratio has gone up 0.4.
Below are key valuation metrics over time for CASI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CASI | 2023-01-20 | 0.7 | 0.4 | -1 | 0.0 |
| CASI | 2023-01-19 | 0.7 | 0.4 | -1 | 0.0 |
| CASI | 2023-01-18 | 0.7 | 0.4 | -1 | 0.0 |
| CASI | 2023-01-17 | 0.8 | 0.5 | -1 | -0.1 |
| CASI | 2023-01-13 | 0.7 | 0.4 | -1 | 0.0 |
| CASI | 2023-01-12 | 0.7 | 0.4 | -1 | -0.1 |
CASI Growth Metrics
- The 2 year net income to common stockholders growth rate now stands at 32.25%.
- Its 3 year price growth rate is now at -90.19%.
- The 5 year net cashflow from operations growth rate now stands at -270.66%.
The table below shows CASI's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 37.006 | -27.886 | -27.078 |
| 2022-06-30 | 34.905 | -25.222 | -32.101 |
| 2022-03-31 | 33.494 | -23.079 | -31.367 |
| 2021-12-31 | 30.168 | -26.842 | -36.654 |
| 2021-09-30 | 25.832 | -27.233 | -45.252 |
| 2021-06-30 | 21.962 | -30.203 | -51.981 |
CASI's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CASI has a Quality Grade of F, ranking ahead of 3.6% of graded US stocks.
- CASI's asset turnover comes in at 0.158 -- ranking 218th of 682 Pharmaceutical Products stocks.
- DRNA, RARE, and ALNY are the stocks whose asset turnover ratios are most correlated with CASI.
The table below shows CASI's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.158 | 0.585 | -0.969 |
| 2021-03-31 | 0.139 | 0.505 | -1.192 |
| 2020-12-31 | 0.134 | 0.372 | -1.351 |
| 2020-09-30 | 0.109 | 0.242 | -1.615 |
| 2020-06-30 | 0.101 | 0.053 | -1.638 |
| 2020-03-31 | 0.070 | 0.052 | -2.024 |
CASI Price Target
For more insight on analysts targets of CASI, see our CASI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $4.45 | Average Broker Recommendation | 1.25 (Strong Buy) |
CASI Stock Price Chart Interactive Chart >
CASI Price/Volume Stats
| Current price | $2.04 | 52-week high | $10.30 |
| Prev. close | $1.99 | 52-week low | $1.45 |
| Day low | $2.02 | Volume | 12,200 |
| Day high | $2.05 | Avg. volume | 35,133 |
| 50-day MA | $1.87 | Dividend yield | N/A |
| 200-day MA | $2.94 | Market Cap | 27.76M |
CASI Pharmaceuticals, Inc. (CASI) Company Bio
CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, acquires, develops, and commercializes therapeutics addressing cancer and other unmet medical needs in China. The company was founded in 1991 and is based in Rockville, Maryland.
Latest CASI News From Around the Web
Below are the latest news stories about CASI PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CASI as an investment opportunity.
Casi Pharmaceuticals to run clinical trial for multiple myeloma drug in ChinaMARKET PULSE Shares of Casi Pharmaceuticals Inc. (CASI) were up 10% in premarket trading on Friday after the company said China will allow a Phase 1 clinical trial evaluating a multiple myeloma drug developed by the privately held Cleave Therapeutics. |
CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINACASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces that the China National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (CTA) for CB-5339, a first-in-class VCP/p97 inhibitor from Cleave Therapeutics. CASI is planning a Phase 1 development program in China of CB-5339 as a single agent to evaluate the PK/safety profile, se |
CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATIONCASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that China National Medical Products Administration (NMPA) has accepted the new drug application (NDA) from Juventas Cell Therapy, Ltd., (Juventas) for CNCT19 (Inaticabtagene Autoleucel), an investigational CD-19 directed CAR-T therapy, for the treatment of adult patients with relapsed/refractory B-Cell Acute Ly |
CASI Pharmaceuticals Third Quarter 2022 Earnings: Beats ExpectationsCASI Pharmaceuticals ( NASDAQ:CASI ) Third Quarter 2022 Results Key Financial Results Revenue: US$10.2m (up 26% from 3Q... |
CASI Pharmaceuticals, Inc. (CASI) Reports Q3 Loss, Lags Revenue EstimatesCASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 25.49% and 1.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
CASI Price Returns
| 1-mo | 28.30% |
| 3-mo | 4.62% |
| 6-mo | -17.41% |
| 1-year | -65.42% |
| 3-year | -93.11% |
| 5-year | -94.73% |
| YTD | 13.97% |
| 2022 | -77.63% |
| 2021 | -72.88% |
| 2020 | -4.53% |
| 2019 | -23.13% |
| 2018 | 23.69% |
Loading social stream, please wait...